BVSBVSHealthcare · Medical Devices

BVS Stock Forecast: Bioventus, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$9.88
−0.70% on the day

The 5 Wall Street analysts covering Bioventus, Inc. hold a median 12-month price target of $16 — +61.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 93 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$676.5M
Ticker Nerd rank
93/ 100
Median analyst target
$16
Analysts covering
5
Revenue$153.2M+3.8% y/y
Operating income$18.7M
Net income$36.2M
Free cash flow$18.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.3%
1M
−29.2%
YTD
+32.8%
1Y
+51.3%
From 52W high
−35.3%
From 52W low
+51.3%
$7
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Bioventus, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
93/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
98
Value
91
Momentum
90
Issuance
83
Growth
75
Accruals
74
Volatility
49
Revisions
31

Quality (98): The business earns solid, repeatable profits on what it owns.

Revisions (31): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

BVS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BVS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$6$8$10$12$14$16$18Jan 26Apr 26Jul 26Oct 26BVSHigh $18Median $16Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5
Buy
0
Hold
0
Sell
$15
Low
$16
Median
$18
High

The green dot is the last close — the median target sits +61.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 Nov 2026Canaccord GenuityMaintainsBuy$19 → $18
17 Aug 2026Canaccord GenuityMaintainsBuy$15 → $19
17 Aug 2026Cantor FitzgeraldReiteratesOverweight$15
30 June 2026Barrington ResearchMaintainsOutperform$14
16 June 2026Canaccord GenuityMaintainsBuy—
22 May 2026Barrington ResearchMaintainsOutperform—
6 Mar 2026Barrington ResearchMaintainsOutperform—
6 Mar 2026Craig-HallumMaintainsBuy—
9 Feb 2026Barrington ResearchInitiatesOutperform—
7 July 2025Cantor FitzgeraldInitiatesOverweight—
17 Mar 2025Canaccord GenuityMaintainsBuy—
17 Dec 2024JP MorganUpgradeNeutral—
6 Nov 2024Canaccord GenuityMaintainsBuy—
27 Sept 2024Craig-HallumMaintainsBuy—
13 Aug 2024Canaccord GenuityMaintainsBuy—
7 Aug 2024Craig-HallumMaintainsBuy—
8 May 2024Canaccord GenuityMaintainsBuy—
13 Mar 2024Craig-HallumMaintainsBuy—
7 Dec 2023Canaccord GenuityUpgradeBuy—
3 Apr 2023Craig-HallumMaintainsHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for BVS.

Market Radar

This page is one stock. Monday covers all of them.

BVS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

BVS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Bioventus, Inc. returned +51.3% against +6.9% for the S&P 500, dividends included.

BVS vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26BVSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BVS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−1.5%
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
12.2×

Cheaper than 65% of US stocks

Price / sales
1.2×

Cheaper than 62% of US stocks

Price / book
2.8×

Cheaper than 33% of US stocks

EV / EBITDA
12.1×

Cheaper than 46% of US stocks

Growth & margins
Revenue growth (YoY)
2.7%

Higher than 34% of US stocks

Earnings growth (YoY)
89.8%

Higher than 83% of US stocks

Gross margin
69.0%

Higher than 82% of US stocks

Operating margin
10.1%

Higher than 63% of US stocks

Net margin
9.8%

Higher than 67% of US stocks

Returns & dividend
Return on equity
25.8%

Higher than 85% of US stocks

Return on assets
5.4%

Higher than 77% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Bioventus, Inc. has a market value of $676.5M and an enterprise value of $939.0M.

  • Revenue in the twelve months to 30 June 2026: $581.8M. The latest quarter grew 3.8% year on year.

  • Net income over the same four quarters: $61.5M, a 10.6% net margin.

  • Diluted earnings per share, trailing twelve months: $0.77.

  • Free cash flow in the twelve months to 30 June 2026: $94.3M.

  • Shares outstanding: 68.2M.

  • Trailing P/E: 12.2×; forward P/E: 11.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Bioventus, Inc. employs 960 people — $606K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

BVS and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
BVSBioventus, Inc.$676.5M93
KIDSOrthoPediatrics Corp.$828.7M84
CTKBCytek Biosciences, Inc.$790.4M95
AORTArtivion, Inc.$885.4M31
VREXVarex Imaging Corp.$758.7M81
INMDInMode Ltd.$713.9M85
AHCOAdaptHealth Corp.$978.6M68

Take a look at BVS’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Bioventus, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about BVS

What is the BVS stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Bioventus, Inc. have a median 12-month price target of $16, with estimates ranging from $15 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BVS stock a buy right now?

Of the 5 analysts covering Bioventus, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Bioventus, Inc. 93 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BVS?

As at 21 Nov 2026, Bioventus, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (98 of 100).

Will BVS stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +61.9% from the last close, and Ticker Nerd's factor model ranks Bioventus, Inc. 93 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BVS stock forecast for 2030?

No analyst covering Bioventus, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BVS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $18 over the next 12 months.

How has BVS stock performed over the past year?

Bioventus, Inc. returned +51.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Bioventus, Inc. do?

Bioventus Inc. Class A Common Stock represents Bioventus Inc., a medical technology company focused on developing and commercializing products for musculoskeletal care and active healing. Bioventus serves patients and healthcare providers with orthobiologic and restorative solutions designed to support bone healing, pain treatment, and recovery from a range of orthopedic conditions.

Company

About Bioventus, Inc.

Bioventus Inc. Class A Common Stock represents Bioventus Inc., a medical technology company focused on developing and commercializing products for musculoskeletal care and active healing. Bioventus serves patients and healthcare providers with orthobiologic and restorative solutions designed to support bone healing, pain treatment, and recovery from a range of orthopedic conditions. Its current business is organized around active healing therapies, surgical solutions, and related products used in both U.S. and international markets. The company’s portfolio includes therapies such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture-healing technologies. Bioventus operates as a specialized healthcare company within the broader medical device sector, with offerings aimed at non-surgical and surgical treatment settings.

CEO Mr. Robert E. Claypoole · 960 employees · United States · https://www.bioventus.com